LifeArc boosts investment in Cambridge University spin-out PolyProx Therapeutics to advance new class of cancer medicines

The investment will help advance studies to validate polyproxin® molecules as potential drug candidates across a range of cancers.

LifeArc and Scottish Government Chief Scientist Office launch new funding scheme to boost translational research in Scotland

Funding aims to progress strong discovery science to a point where additional substantive funding could be secured.

LifeArc marks Rare Disease Day 2020 with a call for more translational research

Translational research can turn promising science into new treatments for those with rare diseases. It’s why we…

Celebrating the International Day of Women and Girls in Science

LifeArc celebrates the UN’s International day of Women and Girls in Science, joining the call to remove any barriers that hold women back.

LifeArc and Action Medical Research launch funding call for research into rare diseases in children

£1m for translational research projects focussed on children’s rare diseases

LifeArc appoints new Chief Investment Officer (CIO)

Graham Duce appointed to the newly created role of CIO to ensure that we have a sustainable approach to income generation

Celebrating the successes of UK translation – our 2019 annual reception

Melanie Lee, LifeArc CEO acknowledges the success of the life sciences and translational research sectors in the UK

Patients with ultra-rare bone marrow disease set to benefit from £1.15m grant from LifeArc and The Aplastic Anaemia Trust

A research grant to investigate the potential of a novel type of “personalised cellular therapy” to reverse the ultra-rare condition, aplastic anaemia

LifeArc Seed Fund makes £1.5million investment in Caldan Therapeutics to develop novel treatments for metabolic diseases

Investment to allow Caldan to translate work on free fatty acid receptors initiated in their laboratories